Venus Remedies, headquartered in Panchkula, Haryana (India), is among the 10 leading fixed-dosage injectable manufacturers in the world. The company has three manufacturing units, in Panchkula, Baddi (both India) and Werne (Germany) and 11 overseas marketing offices, including a presence in the US and Germany.
The manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by EUROPEAN-GMP, WHO-GMP, Latin American GMP (INVIMA), Ukrainian GMP, Zimbabwe GMP, Uganda GMP, Syrian GMP, Columbian GMP, Kenya GMP, Yemen GMP, Saudi Arabian GMP and Iranian GMP, among others.
Venus Remedies has been ranked 107th in Asia (source: Bio Spectrum Asia) and among the 500 largest pharmaceutical manufacturing companies in the world (source: Plimsoll Worldwide Business Intelligence Report).
Venus has won over 102 patents for its innovative research products worldwide. The company has presence in 60 countries and covers more than 75 products.
The novel antibiotic adjuvant entity is highly effective against drug-resistant infections, different resistance mechanisms which no other existing therapeutic options available in the market are able to tackle
Vancoplus projected to cater to a market of Rs 214 crore in India by 2018-19... (more)
Gets approval from Swiss drug authority Swissmedic through its German subsidiary Venus Pharma GmbH for meropenem 500 mg, 1 g injections
With plans to launch the product early next year through its partner Swiss Pharma GmbH Zurich, Venus eyes 10% share in Switzerland’s meropenem ma... (more)
Company holding talks with various pharmaceutical firms for tie-ups
Trois has a huge potential in Singapore, where 10% people are diagnosed with arthritis, 73.4% of the office workers suffer from musculoskeletal disorders and 20% of the population above the age of 65 suffers from sympto... (more)
The distribution-cum-outlicensing agreement between Venus Pharma GmbH, Germany and Mylan will enable Venus Remedies to market meropenem in Denmark, Sweden and Finland for five years
While the drug will be manufactured at Venus Remedies’ Baddi facility, batch release and logistics ... (more)
Venus will initially manufacture the drug at the Venus Medicine Research Centre, its research unit, for assisting Teva in registrations, after which the company will use its manufacturing capabilities to support Teva in enhancing business from this drug in Canada
Being among the first few pharma firms to receive marketing authorisation for Gemcitabine, an oncology drug, and the first Indian company to get marketing approval for this product from Switzerland, Venus Remedies enjoys a competitive edge over other players and is all set to capture a substantia... (more)
